`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE SOUTHERN DISTRICT OF INDIANA
`INDIANAPOLIS DIVISION
`
`Civil Action No. 1:16-cv-308
`
`))
`
`)
`)
`)
`)
`
`))
`
`)
`
`ELI LILLY AND COMPANY,
`
`v.
`
`Plaintiff,
`
`DR. REDDY’S LABORATORIES, LTD. and
`DR. REDDY’S LABORATORIES, INC.,
`
`Defendants.
`
`COMPLAINT
`
`Plaintiff Eli Lilly and Company (“Lilly”), by its attorneys, hereby alleges as
`
`follows:
`
`NATURE OF THE ACTION
`
`1.
`
`This is an action for patent infringement under the patent laws of the
`
`United States, Title 35, United States Code, that arises out of the filing by defendant Dr. Reddy’s
`
`Laboratories, Inc. on behalf of defendant Dr. Reddy’s Laboratories, Ltd. (collectively, “DRL”) of
`
`a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”)
`
`seeking approval to manufacture and sell its Pemetrexed for Injection 100 mg/vial and 500
`
`mg/vial products (“DRL’s NDA Products”) prior to the expiration of U.S. Patent No. 7,772,209
`
`(“the ’209 patent”). DRL notified Lilly that it had submitted to the FDA NDA No. 208297 for
`
`DRL’s NDA Products by letter dated December 22, 2015 (“DRL’s Notice Letter” or “Notice
`
`Letter”). Upon information and belief, DRL’s NDA Products will be marketed as competing
`
`products to ALIMTA®, a chemotherapy agent developed and distributed by Lilly and used for
`
`the treatment of various types of cancer.
`
`
`
`Case 1:16-cv-00308-TWP-DKL Document 1 Filed 02/05/16 Page 2 of 10 PageID #: 2
`
`PARTIES
`
`2.
`
`Lilly is a corporation organized and existing under the laws of the State of
`
`Indiana, having its corporate offices and place of business at Lilly Corporate Center,
`
`Indianapolis, Indiana 46285.
`
`3.
`
`Upon information and belief, Dr. Reddy’s Laboratories, Ltd. is a
`
`corporation organized and existing under the laws of India, having a place of business at 8-2-
`
`337, Road No. 3, Banjara Hills, Hyderabad, India 500034.
`
`4.
`
`Upon information and belief, Dr. Reddy’s Laboratories, Inc. is a
`
`corporation organized and existing under the laws of the State of New Jersey, having a place of
`
`business at 107 College Road East, Princeton, New Jersey 08540. Upon information and belief,
`
`Dr. Reddy’s Laboratories, Inc. is in the business of manufacturing, marketing, and selling
`
`generic drug products.
`
`5.
`
`Upon information and belief, Dr. Reddy’s Laboratories, Inc. is a wholly-
`
`owned subsidiary of Dr. Reddy’s Laboratories, Ltd. Upon information and belief, Dr. Reddy’s
`
`Laboratories, Inc. and Dr. Reddy’s Laboratories, Ltd. are agents and/or alter-egos of one another,
`
`operate in concert as integrated parts of the same business group, and enter or have entered into
`
`agreements with each other that are nearer than arm’s length, including with respect to the
`
`manufacture, importation, marketing, sale, and distribution of DRL’s NDA Products.
`
`JURISDICTION AND VENUE
`
`6.
`
`This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331,
`
`1338(a), 2201, and 2202.
`
`7.
`
`Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400(b).
`
`2
`
`
`
`Case 1:16-cv-00308-TWP-DKL Document 1 Filed 02/05/16 Page 3 of 10 PageID #: 3
`
`8.
`
`Upon information and belief, Dr. Reddy’s Laboratories, Ltd. is a generic
`
`pharmaceutical company in India engaged in developing, manufacturing, marketing, selling, and
`
`distributing a broad range of pharmaceutical products globally. Upon information and belief, a
`
`substantial number of these products are marketed throughout the United States, including in the
`
`State of Indiana. Upon information and belief, Dr. Reddy’s Laboratories, Ltd. operates its
`
`manufacturing, marketing, sales, and distribution infrastructure in the United States through Dr.
`
`Reddy’s Laboratories, Inc. as a vertically-integrated company.
`
`9.
`
`Upon information and belief, Dr. Reddy’s Laboratories, Inc. performs
`
`functions relating to Dr. Reddy’s Laboratories, Ltd., including manufacturing, marketing, and
`
`sales. Lee Banks, Esq., who is listed in DRL’s Notice Letter as the Vice President, Intellectual
`
`Property of Dr. Reddy’s Laboratories, Inc., is designated as the agent of Dr. Reddy’s
`
`Laboratories, Ltd. for service of process with respect to this litigation. Upon information and
`
`belief, Dr. Reddy’s Laboratories, Inc. participated with Dr. Reddy’s Laboratories, Ltd. in the
`
`preparation, review, and/or submission of NDA No. 208297.
`
`10.
`
`Upon information and belief, Dr. Reddy’s Laboratories, Inc. is engaged in
`
`the manufacturing, marketing, and sale of generic pharmaceutical products for the U.S.
`
`prescription drug market on behalf of Dr. Reddy’s Laboratories, Ltd. Upon information and
`
`belief, Dr. Reddy’s Laboratories, Ltd. provides Dr. Reddy’s Laboratories, Inc. with products for
`
`sale in the United States. Upon information and belief, those products are then marketed, sold,
`
`and distributed to oncologists, clinics, and hospitals throughout the United States, including in
`
`Indiana, as well as to wholesalers, who sell, with Dr. Reddy’s Laboratories, Ltd.’s knowledge,
`
`Dr. Reddy’s Laboratories Ltd.’s products, including in Indiana. Upon information and belief,
`
`3
`
`
`
`Case 1:16-cv-00308-TWP-DKL Document 1 Filed 02/05/16 Page 4 of 10 PageID #: 4
`
`Dr. Reddy’s Laboratories, Inc. or its affiliates will distribute DRL’s NDA Products in the United
`
`States, including in Indiana, upon approval of NDA No. 208297.
`
`11.
`
`Upon information and belief, DRL has previously used the process
`
`contemplated by the Food, Drug, and Cosmetic Act (the “FDCA”), 21 U.S.C. § 355(b) and the
`
`Drug Price Competition Term Restoration Act of 1984, 21. U.S.C. § 355(j) (the “Hatch-Waxman
`
`Act”), to challenge branded pharmaceutical companies’ patents by filing a certification of the
`
`type described in Section 505(b)(2)(A)(iv) or 505(j)(2)(A)(vii)(IV), serving a notice letter on
`
`those companies, and engaging in patent litigation arising from the processes contemplated by
`
`those acts. Upon information and belief, as of March 31, 2015, DRL had cumulative filings of
`
`735 Drug Master Files and 220 Abbreviated New Drug Applications (“ANDAs”), of which 68
`
`were pending approval.
`
`12.
`
`Upon information and belief, DRL has availed itself of the legal
`
`protections of the state of Indiana by filing claims or counterclaims affirmatively seeking relief
`
`in other prior actions in this Court.
`
`13.
`
`Upon information and belief, with knowledge of the processes described
`
`in the FDCA and the Hatch-Waxman Act, DRL directed its Notice Letter to Lilly, an entity
`
`incorporated in Indiana, at its corporate headquarters in Indiana, and alleged in the Notice Letter
`
`the invalidity, unenforceability, and/or non-infringement of Lilly’s ’209 patent. Upon
`
`information and belief, DRL deliberately challenged Lilly’s patent rights, and knew when it did
`
`so that it was triggering a forty-five-day period for Lilly to bring an action for patent
`
`infringement under the FDCA. Moreover, upon information and belief, DRL knew that other
`
`FDCA and/or Hatch-Waxman Act infringement actions relating to the ’209 patent had been
`
`brought and litigated in Indiana.
`
`4
`
`
`
`Case 1:16-cv-00308-TWP-DKL Document 1 Filed 02/05/16 Page 5 of 10 PageID #: 5
`
`14.
`
`Because Lilly is incorporated and has its principal place of business in
`
`Indiana, the injury and consequences of DRL’s filing of NDA No. 208297, challenging Lilly’s
`
`patent rights, are suffered in Indiana. Upon information and belief, DRL knew that it was
`
`deliberately challenging the patent rights of an Indiana entity and seeking to challenge
`
`intellectual property held in Indiana and that the effects of any successful challenge of the ’209
`
`patent would be felt by Lilly in Indiana.
`
`15.
`
`Upon information and belief, if NDA No. 208297 is approved, DRL will
`
`directly or indirectly market and/or sell DRL’s NDA Products within the United States, including
`
`in Indiana, consistent with DRL’s practices for the marketing and distribution of other
`
`pharmaceutical products on its own or through its affiliates. Upon information and belief, DRL
`
`and/or its affiliates regularly do business in Indiana, and their practices with other
`
`pharmaceutical products have involved the distribution of DRL products, directly or indirectly,
`
`throughout the United States, including in Indiana. Upon information and belief, DRL’s
`
`pharmaceutical products are used and/or consumed within and throughout the United States,
`
`including Indiana.
`
`16.
`
`Upon information and belief, DRL and its affiliates derive substantial
`
`revenue from pharmaceutical products that are used and/or consumed within Indiana, and which
`
`are manufactured by DRL or its affiliates and/or for which DRL is the named applicant on
`
`approved NDAs or ANDAs. Upon information and belief, various products for which DRL, or
`
`its affiliates, is the named applicant on approved NDAs and ANDAs are available at pharmacies
`
`in Indiana.
`
`17.
`
`Upon information and belief, if NDA No. 208297 is approved, DRL’s
`
`NDA Products, under the direction and control of physicians practicing in Indiana, will be
`
`5
`
`
`
`Case 1:16-cv-00308-TWP-DKL Document 1 Filed 02/05/16 Page 6 of 10 PageID #: 6
`
`administered to patients of Indiana. These activities, as well as DRL’s marketing, selling, and/or
`
`distributing of DRL’s NDA Products, would have a substantial effect within Indiana and would
`
`constitute infringement of Lilly’s patent in the event that DRL’s NDA Products are approved
`
`before the ’209 patent expires.
`
`18.
`
`For the reasons described above, among others, this Court may properly
`
`exercise personal jurisdiction over Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories,
`
`Inc.
`
`19.
`
`Alternatively, if the exercise of personal jurisdiction over Dr. Reddy’s
`
`Laboratories Ltd. in this Court is not held to be proper, then, upon information and belief, Dr.
`
`Reddy’s Laboratories, Ltd. is not subject to jurisdiction in any state’s courts of general
`
`jurisdiction, and there is therefore personal jurisdiction over Dr. Reddy’s Laboratories, Ltd. in
`
`this Court pursuant to Fed. R. Civ. P. 4(k)(2).
`
`BACKGROUND
`
`20.
`
`ALIMTA® is indicated (in combination with cisplatin) (a) for the
`
`treatment of patients with malignant pleural mesothelioma, or (b) for the initial treatment of
`
`locally advanced or metastatic nonsquamous non-small cell lung cancer. ALIMTA® also is
`
`indicated as a single-agent for the treatment of patients with locally advanced or metastatic
`
`nonsquamous non-small cell lung cancer after prior chemotherapy. ALIMTA® also is indicated
`
`for maintenance treatment of patients with locally advanced or metastatic nonsquamous non-
`
`small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-
`
`line chemotherapy.
`
`21.
`
`Lilly sells ALIMTA® in the United States pursuant to a New Drug
`
`Application that has been approved by the FDA.
`
`6
`
`
`
`Case 1:16-cv-00308-TWP-DKL Document 1 Filed 02/05/16 Page 7 of 10 PageID #: 7
`
`22.
`
`The ’209 patent, titled “Antifolate Combination Therapies,” was duly and
`
`legally issued on August 10, 2010. The ’209 patent is attached as Exhibit A.
`
`23.
`
`24.
`
`Lilly is the assignee of the ’209 patent.
`
`An actual case or controversy exists between Lilly and DRL with respect
`
`to infringement of the ’209 patent.
`
`25.
`
`This action is being filed within 45 days of Lilly’s receipt of DRL’s
`
`Notice Letter.
`
`herein.
`
`COUNT
`
`(Infringement of U.S. Patent No. 7,772,209)
`
`26.
`
`Lilly incorporates each of the preceding paragraphs as if fully set forth
`
`27.
`
`Upon information and belief, DRL’s NDA Products contain pemetrexed
`
`disodium or its equivalent.
`
`28.
`
`Upon information and belief, the proposed labeling for DRL’s NDA
`
`Products involves administration of folic acid and vitamins B12.
`
`29.
`
`Upon information and belief, the use of DRL’s NDA Products in
`
`accordance with and as directed by DRL’s proposed labeling for those products will infringe
`
`claims 1-22 of the ’209 patent, either literally or under the doctrine of equivalents.
`
`30.
`
`Upon information and belief, DRL filed as part of NDA No. 208297 a
`
`certification of the type described in Section 505(b)(2)(A)(iv) of the FDCA, 21 U.S.C. §
`
`355(b)(2)(A)(iv), asserting that the claims of the ’209 patent are invalid, unenforceable, and/or
`
`not infringed by the manufacture, use, offer for sale, or sale of DRL’s NDA Products.
`
`7
`
`
`
`Case 1:16-cv-00308-TWP-DKL Document 1 Filed 02/05/16 Page 8 of 10 PageID #: 8
`
`31.
`
`The purpose of NDA No. 208297 was to obtain approval under the FDCA
`
`to engage in the commercial manufacture, use, offer for sale, and/or sale of DRL’s NDA
`
`Products prior to the expiration of the ’209 patent.
`
`32.
`
`DRL’s submission of NDA No. 208297 for the purpose of obtaining
`
`approval to engage in the commercial manufacture, use, offer for sale, and/or sale of DRL’s
`
`NDA Products prior to the expiration of the ’209 patent is an act of infringement of the ’209
`
`patent under 35 U.S.C. § 271(e)(2)(A).
`
`33.
`
`Upon information and belief, DRL intends to engage in the manufacture,
`
`use, offer for sale, sale, marketing, distribution, and/or importation of DRL’s NDA Products and
`
`the proposed labeling therefor immediately and imminently upon approval of NDA No. 208297,
`
`i.e., prior to the expiration of the ’209 patent.
`
`34.
`
`Upon information and belief, DRL has knowledge of the claims of the
`
`’209 patent. Notwithstanding this knowledge, DRL has continued to assert its intent to engage in
`
`the manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of DRL’s
`
`NDA Products and the proposed labeling therefor immediately and imminently upon approval of
`
`NDA No. 208297.
`
`35.
`
`Upon information and belief, DRL plans and intends to, and will, actively
`
`induce infringement of the ’209 patent when its NDA is approved, and plans and intends to, and
`
`will, do so immediately and imminently upon approval.
`
`36.
`
`Upon information and belief, DRL knows that DRL’s NDA Products are
`
`especially made or adapted for use in infringing the ’209 patent, and that DRL’s NDA Products
`
`are not suitable for substantial noninfringing use. Upon information and belief, DRL plans and
`
`8
`
`
`
`Case 1:16-cv-00308-TWP-DKL Document 1 Filed 02/05/16 Page 9 of 10 PageID #: 9
`
`intends to, and will, contribute to infringement of the ’209 patent immediately and imminently
`
`upon approval of NDA No. 208297.
`
`37.
`
`The foregoing actions by DRL constitute and/or will constitute
`
`infringement of the ’209 patent, active inducement of infringement of the ’209 patent, and
`
`contribution to the infringement by others of the ’209 patent.
`
`38.
`
`Unless DRL is enjoined from infringing the ’209 patent, actively inducing
`
`infringement of the ’209 patent, and contributing to the infringement by others of the ’209
`
`patent, Lilly will suffer irreparable injury. Lilly has no adequate remedy at law.
`
`WHEREFORE, Lilly requests the following relief:
`
`(a)
`
`A judgment that DRL has infringed the ’209 patent and/or will infringe,
`
`actively induce infringement of, and/or contribute to infringement by others of the ’209 patent;
`
`(b)
`
`A judgment ordering that the effective date of any FDA approval for DRL
`
`to make, use, offer for sale, sell, market, distribute, or import DRL’s NDA Products, or any
`
`product the use of which infringes the ’209 patent, be not earlier than the expiration date of the
`
`’209 patent, inclusive of any extension(s) and additional period(s) of exclusivity;
`
`(c)
`
`A preliminary and permanent injunction enjoining DRL, and all persons
`
`acting in concert with DRL, from making, using, selling, offering for sale, marketing,
`
`distributing, or importing DRL’s NDA Products, or any product the use of which infringes the
`
`’209 patent, or the inducement of or contribution to any of the foregoing, prior to the expiration
`
`date of the ’209 patent, inclusive of any extension(s) and additional period(s) of exclusivity;
`
`(d)
`
`A judgment declaring that making, using, selling, offering for sale,
`
`marketing, distributing, or importing of DRL’s NDA Products, or any product the use of which
`
`infringes the ’209 patent, prior to the expiration date of the ’209 patent, infringes, will infringe,
`
`9
`
`
`
`Case 1:16-cv-00308-TWP-DKL Document 1 Filed 02/05/16 Page 10 of 10 PageID #: 10
`
`will actively induce infringement of, and/or will contribute to the infringement by other of the
`
`’209 patent;
`
`(e)
`
`A declaration that this is an exceptional case and an award of attorneys’
`
`fees pursuant to 35 U.S.C. § 285;
`
`(f)
`
`(g)
`
`An award of Lilly’s costs and expenses in this action; and
`
`Such further and other relief as this Court may deem just and proper.
`
`Dated: February 5, 2016
`
`/s/ Jan M. Carroll
`Jan M. Carroll, No. 4187-49
`BARNES & THORNBURG LLP
`11 South Meridian Street
`Indianapolis, IN 46204
`(317) 236-1313
`jan.carroll@btlaw.com
`Attorney for Plaintiff
`Eli Lilly and Company
`
`DMS 3664612v1
`
`10
`
`